---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-024400"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2023-07-13T23:59:59+00:00"
generated_at: "2026-06-13T08:55:48.830230+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biofrontera Q2 2023 preliminary revenue $5.7M-$5.9M, up 26%-31% YoY; reaffirms FY growth 25%

## Summary
- Q2 2023 preliminary revenue range $5.7M-$5.9M, a 26%-31% increase over Q2 2022.
- H1 2023 revenue estimated at $14.4M-$14.6M, reflecting 1%-3% growth YoY.
- Full-year 2023 revenue growth reaffirmed at least 25% over 2022.
- Management cites increasing adoption of photodynamic therapy and larger contract wins.

## SEC filing metadata
- accession: 0001493152-23-024400
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2023-07-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315223024400/0001493152-23-024400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315223024400/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-024400
- JSON: https://secwatch.observer/filing/0001493152-23-024400.json
- Plain text: https://secwatch.observer/filing/0001493152-23-024400.txt

## Key facts
- Earnings Releases
  Biofrontera Inc. reported the six months ended June 30, 2023 results: revenue in the range of approximately $14.4 million to $14.6 million. Guidance reaffirmed.
  - Period: the six months ended June 30, 2023
  - Revenue: in the range of approximately $14.4 million to $14.6 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: of approximately 26% to 31% compared with the second quarter of 2022. As a result, revenues for the first half of 2023 are anticipated to be in the range of approximately $14.4 million to $14.6 million, representing growth of approximately 1% to 3% compared with the first half of 2022. “We are proud of the hard work of our commercial teams, which resulted in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315223024400/0001493152-23-024400-index.htm
- Earnings Releases
  Biofrontera Inc. reported the three months ended June 30, 2023 results: revenue in the range of approximately $5.7 million to $5.9 million. Guidance reaffirmed.
  - Period: the three months ended June 30, 2023
  - Revenue: in the range of approximately $5.7 million to $5.9 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: announced preliminary unaudited revenues for the three months ended June 30, 2023. Revenues for the second quarter of 2023 are anticipated to be in the range of approximately $5.7 million to $5.9 million, an increase of approximately 26% to 31% compared with the second quarter of 2022. As a result, revenues for the first half of 2023 are anticipated to be in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315223024400/0001493152-23-024400-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.